Medical Therapeutics

Artris Therapeutics, Inc.

Brief Description

Artris Therapeutics was founded to identify and develop cancer therapeutics. The company was co-founded by UC Berkeley Professor of Chemical Biology and Molecular Therapeutics Daniel Nomura.

Timeline

2017. Company founded Inventors

Leslie Bateman, Jessica Cestellos Spradlin, Tucker Huffman, David Miyamoto, Elizabeth Anne Moore, Truc Bang Nguyen, Daniel Nomura, James Arthur Olzmann, Allison Marie Roberts, Carl Ward

Algen Biotechnologies

Brief Description

Algen Biotechnologies is building a next-generation, functional genomics-based platform for the discovery of novel therapeutics for cancers with high unmet need. Algen’s research group focuses on developing and applying novel functional genomics technologies to address scientific challenges in drug discovery. The company's biologists and data scientists are collaborating to deliver innovative, patient-centric medicines for the toughest-to-treat diseases.

The company was founded to commercialize technology developed at UC Berkeley while Algen Biotechnologies CEO...

Ansa Biotechnologies

Brief Description

With synthetic DNA fueling innovation in biological research, therapeutics, diagnostics, and biomanufacturing, there is an urgent need for faster and more accurate DNA synthesis. Currently, DNA is manufactured via a chemical method that has remained essentially unchanged for 35 years and has approached a plateau. Ansa Biotechnologies is developing a faster, more accurate, and cleaner enzyme-based DNA synthesis technology. The technique promises to dramatically accelerate innovation in biological research and engineering.

The approach is based on polymerase-...

Juvenon, Inc.

Brief Description

UC Berkeley scientists founded Juvenon to make their healthy aging breakthrough available to the public. The company's patented combination of natural micronutrients promotes a healthier, more energetic body and protects tissue from the toxic oxidants that increase with normal daily stress-producing activities and exercise, as well as with the aging process. Juvenon has expanded to multiple products that enable consumers to maintain vigor and functionality as they age, empowering millions of individuals worldwide to live better longer, and age gracefully.

The...

Singulex, Inc.

Brief Description

Singulex is an immunodiagnostics company at the forefront of Single Molecule Counting technology, a novel immunoassay technology recognized for unprecedented ultra sensitivity in the precision measurement of biomarkers. Singulex is the developer of the Singulex Clarity system, a fully automated, in vitro diagnostics platform powered by Single Molecule Counting technology. With up to 1,000 times more sensitivity than existing technologies, Single Molecule Counting reveals the presence or absence of disease more clearly and definitively than was possible before. The...

OptoCeutics

Brief Description

Advancing non-invasive light technologies to stimulate the brain and improve cognitive function.

Through clinical trials, Optoceutics tests and develop solutions to treat and diagnose neurodegenerative diseases using emerging gamma stimulation therapy and digital biomarkers.

40 Hz light for gamma stimulation has been shown to improve memory and cognitive performance in a mouse model of Alzheimer's disease. 40 Hz light stimulation reduced amyloid plaque associated with Alzheimer's disease in the brain of mice by about 50%. Optoceutics develops a masked 40 Hz...

OncoRx Pharmaceuticals, Inc.

Brief Description

OncoRx Pharmaceuticals is an early-stage pharmaceutical company discovering and developing targeted therapies that control the progression of invasive malignant cancer. OncoRx has identified and tested drugs that markedly alter the sustained directional mobility, the uncontrolled cell cycle, and t​​he unrestrained growth and proliferation of intrinsically and acquired therapy-resistant tumors. Unlike non-aggressive primary tumors, the growth, progression and invasiveness of therapy-resistant tumors are not effectively controlled with currently available cancer therapies...

Libraria, Inc.

Brief Description

Libraria Inc. is using computational techniques to discover new small-molecule drugs that can be administered orally. Its proprietary technology enables the company and its partners to leverage known molecular structures, chemistry protocols, and bioactivity data to speed the chemistry phase of drug discovery by up to 50%.

Timeline

2000. Company founded.

2003. Acquired by Eidogon-Sertanty.

Inventors Jonathan Ellman

Iris Micromedical, Inc.

Brief Description

Drug delivery based on microstructural devices that administer therapeutic agents to selected target sites for treatment.

Iris Micromedical was focused on the development of UC Berkeley Associate Professor of Engineering Mauro Ferrari's silicon particulate technology for the intravascular targeted treatment of cancer imedd.

Four years after founding Iris Micromedical, Dr. Ferrari moved to Ohio State University as a professor of bioengineering, internal medicine, and mechanical engineering, and reformed the company as IMedd, Inc.

Timeline 1995....

Intellia

BRIEF DESCRIPTION Intellia is a leading genome editing company focused on the development of proprietary, potentially curative therapeutics utilizing a recently developed biological tool known as the CRISPR/Cas9 system. Intellia leverages leading scientific expertise, clinical development experience, and intellectual property position to unlock broad therapeutic applications of CRISPR/Cas9 genome editing and develop a potential new drug class. Timeline 2014. Company founded. INVENTOR Jennifer Doudna